• 99% Purity CAS 179324-69-7 Bortezomib API Bortezomib Powder Bortezomib
  • 99% Purity CAS 179324-69-7 Bortezomib API Bortezomib Powder Bortezomib
  • 99% Purity CAS 179324-69-7 Bortezomib API Bortezomib Powder Bortezomib
  • 99% Purity CAS 179324-69-7 Bortezomib API Bortezomib Powder Bortezomib
  • 99% Purity CAS 179324-69-7 Bortezomib API Bortezomib Powder Bortezomib
  • 99% Purity CAS 179324-69-7 Bortezomib API Bortezomib Powder Bortezomib

99% Purity CAS 179324-69-7 Bortezomib API Bortezomib Powder Bortezomib

Powder: Yes
Customized: Customized
Certification: GMP, HSE, ISO 9001, USP, BP
Suitable for: Elderly, Children, Adult
State: Powder
Purity: >99%
Samples:
US$ 50/kg 1 kg(Min.Order)
| Request Sample
Customization:
Diamond Member Since 2021

Suppliers with verified business licenses

Manufacturer/Factory
  • Overview
  • Product Description
  • Product Details
  • Application&Function
  • Specification
Overview

Basic Info.

Model NO.
D-sung Bortezomib
Product Name
Bortezomib
Name
Bortezomib Powder
Appearance
White or off-White Powder
Color
White
Grade
Pharmaceutical Grade
Assay
HPLC 99%
Application
Anti Tumor;Antineoplastic
Specific
COA
Test Method
HPLC
Shelf Life
2 Years
CAS No.
179324-69-7
Mf
C19h25bn4o4
MW
384.23700
Melting Point
122-124°c
Density
1.214
Transport Package
Negotiable
Specification
99%
Trademark
D-sung
Origin
Shaanxi Xi′an
Production Capacity
1000kg/Month

Product Description

99% Purity CAS 179324-69-7 Bortezomib API Bortezomib Powder Bortezomib
99% Purity CAS 179324-69-7 Bortezomib API Bortezomib Powder Bortezomib
Product Description
99% Purity CAS 179324-69-7 Bortezomib API Bortezomib Powder Bortezomib99% Purity CAS 179324-69-7 Bortezomib API Bortezomib Powder Bortezomib
Product Details
99% Purity CAS 179324-69-7 Bortezomib API Bortezomib Powder Bortezomib
Product name Bortezomib
Cas number 179324-69-7
Apperance White or off-white powder
MF C19H25BN4O4
MW 384.23700
Bortezomib is a reversible inhibitor of the chymase-like activity of 26S protease in mammalian cells. In vitro tests demonstrated that bortezomib is cytotoxic to many types of cancer cells. Preclinical tumor models In vivo testing demonstrates that bortezomib delays tumor growth, including multiple myeloma. This product is used in the treatment of patients with multiple myeloma, the effectiveness is based on its efficiency.
Application&Function
99% Purity CAS 179324-69-7 Bortezomib API Bortezomib Powder BortezomibBortezomib, a modified dipeptidyl boronic acid, is a therapeutic proteasome inhibitors used for the treatment of cancers. It is indicated for the treatment of relapsed multiple myeloma and mantle cell lymphoma. It is capable of inhibiting the mammalian 26S proteasome, which is important in regulating the intracellular concentration of specific proteins to maintain homeostasis within cells. The disruption of 26S proteasome function disrupts normal cellular homeostasis, leading to cytotoxic effect on various kinds of cancer cells. 
Specification
99% Purity CAS 179324-69-7 Bortezomib API Bortezomib Powder Bortezomib99% Purity CAS 179324-69-7 Bortezomib API Bortezomib Powder Bortezomib99% Purity CAS 179324-69-7 Bortezomib API Bortezomib Powder Bortezomib
99% Purity CAS 179324-69-7 Bortezomib API Bortezomib Powder Bortezomib99% Purity CAS 179324-69-7 Bortezomib API Bortezomib Powder Bortezomib99% Purity CAS 179324-69-7 Bortezomib API Bortezomib Powder Bortezomib
99% Purity CAS 179324-69-7 Bortezomib API Bortezomib Powder Bortezomib
 
 

Send your message to this supplier

*From:
*To:
*Message:

Enter between 20 to 4,000 characters.

This is not what you are looking for? Post a Sourcing Request Now

You Might Also Like

Diamond Member Since 2021

Suppliers with verified business licenses

Manufacturer/Factory
Management System Certification
ISO 9001, ISO 14001, GMP, HACCP